CLINICAL_TRIALS trial_result · 2020-10-08

Clinical Trial Update: Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia [Phase 2, Phase 3]

A multicenter Phase 2/3 trial evaluating SER120 nasal spray formulations in adults with nocturia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Serenity Pharmaceuticals, Inc. | Conditions: Nocturia | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2020-10-08